In a substudy of SURMOUNT-1, tirzepatide reduced ambulatory blood pressure in adults with a BMI ≥27 kg/m² compared with placebo.
AHA 2023 Deepak Gupta talks about the novel insights that the CARDIA-SSBP study provides on the effects of dietary sodium reduction on blood pressure.
AHA 2023 In the absence of curative therapies for dementia, it was investigated whether a BP-lowering intervention can reduce the risk of dementia in patients with hypertension in China.
AHA 2023 In middle-aged individuals, a low-sodium diet significantly lowered SBP already within a week compared to the participants’ usual diet. The SBP reduction was independent of anti-hypertensive medication use and hypertension status.
AHA 2023 In the POP-HT trial, self-monitoring of BP in combination with physician guided anti-hypertensive medication adjustment during the first 6 weeks postpartum led to improvements in BP up to 9 months after a hypertensive pregnancy.
In a meta-analysis of 7 nonexperimental cohort studies, there was a positive, almost linear association with no evidence of a threshold between alcohol consumption at baseline and systolic blood pressure levels during follow-up in healthy persons.
A greater than 15 mmHg reduction in 24-h ambulatory systolic BP was reported with the two highest single doses of the siRNA therapeutic zilebesiran, targeting hepatic angiotensinogen synthesis, at month 3 compared with placebo in the KARDIA 1 phase 2 trial.
The 2023 European Society of Hypertension (ESH) guidelines for the management of arterial hypertension has been published.
In the PHYSIC trial, systolic blood pressure (SBP) response to 4 widely used antihypertensive drug classes varied considerably. Personalized treatment had the potential to lower SBP by 4.4 mmHg compared with a fixed drug choice.
A serial cross-sectional analysis using data of the NHANES database investigated whether the prevalence of CV risk factors among young US adults changed from 2009 to March 2020.
An analysis of 32,019 individuals showed stronger associations between triglyceride (TG) levels and hypertension, SBP , BMI, or waist circumference in those of European ancestry compared with West African ancestry with minimal or no influence by environmental context, contrary to the associations with T2DM or fasting glucose.
A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.